PL3075855T3 - Liposomy retinoidowe do wzmacniania modulacji ekspresji hsp47 - Google Patents

Liposomy retinoidowe do wzmacniania modulacji ekspresji hsp47

Info

Publication number
PL3075855T3
PL3075855T3 PL16169874T PL16169874T PL3075855T3 PL 3075855 T3 PL3075855 T3 PL 3075855T3 PL 16169874 T PL16169874 T PL 16169874T PL 16169874 T PL16169874 T PL 16169874T PL 3075855 T3 PL3075855 T3 PL 3075855T3
Authority
PL
Poland
Prior art keywords
retinoid
liposomes
hsp47 expression
enhancing modulation
enhancing
Prior art date
Application number
PL16169874T
Other languages
English (en)
Inventor
Violetta AKOPIAN
Kenjiro Minomi
Yoshiro Niitsu
Joseph E. Payne
Victor Knopov
Richard P. WITTE
Mohammad Ahmadian
Loren A. PERELMAN
Yasunobu Tanaka
Elena Feinstein
Sharon Avkin-Nachum
Hagar Kalinski
Igor Mett
Wenbin Ying
Yun LUI
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Publication of PL3075855T3 publication Critical patent/PL3075855T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
PL16169874T 2011-06-08 2012-06-08 Liposomy retinoidowe do wzmacniania modulacji ekspresji hsp47 PL3075855T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161494832P 2011-06-08 2011-06-08
US201161497447P 2011-06-15 2011-06-15
EP12730301.4A EP2717921B1 (en) 2011-06-08 2012-06-08 Retinoid-liposomes for enhancing modulation of hsp47 expression
EP16169874.1A EP3075855B1 (en) 2011-06-08 2012-06-08 Retinoid-liposomes for enhancing modulation of hsp47 expression
PCT/US2012/041761 WO2012170957A2 (en) 2011-06-08 2012-06-08 Retinoid-liposomes for enhancing modulation of hsp47 expression

Publications (1)

Publication Number Publication Date
PL3075855T3 true PL3075855T3 (pl) 2019-02-28

Family

ID=46395700

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12730301.4T PL2717921T3 (pl) 2011-06-08 2012-06-08 Liposomy retinoidowe do wzmacniania modulacji ekspresji hsp47
PL16169874T PL3075855T3 (pl) 2011-06-08 2012-06-08 Liposomy retinoidowe do wzmacniania modulacji ekspresji hsp47

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12730301.4T PL2717921T3 (pl) 2011-06-08 2012-06-08 Liposomy retinoidowe do wzmacniania modulacji ekspresji hsp47

Country Status (21)

Country Link
US (4) US8664376B2 (pl)
EP (2) EP2717921B1 (pl)
JP (1) JP5873168B2 (pl)
KR (1) KR102002771B1 (pl)
CN (1) CN103781909B (pl)
AU (1) AU2012267472B2 (pl)
CA (1) CA2836925C (pl)
CY (2) CY1117683T1 (pl)
DK (2) DK2717921T3 (pl)
ES (2) ES2586593T3 (pl)
HR (1) HRP20181440T8 (pl)
HU (1) HUE039379T2 (pl)
LT (1) LT3075855T (pl)
PL (2) PL2717921T3 (pl)
PT (2) PT3075855T (pl)
RS (1) RS57824B1 (pl)
RU (1) RU2628694C2 (pl)
SI (1) SI3075855T1 (pl)
SM (1) SMT201800584T1 (pl)
TW (1) TWI658830B (pl)
WO (1) WO2012170957A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) * 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20160038593A1 (en) * 2004-12-22 2016-02-11 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
DK2509991T3 (en) 2009-12-09 2015-12-21 Nitto Denko Corp MODULATION OF HSP47 EXPRESSION
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
CN107082747B (zh) * 2011-06-08 2020-11-20 日东电工株式会社 用于定向药物输送和增强siRNA活性的化合物
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US20140323550A1 (en) * 2011-11-18 2014-10-30 Nitto Denko Corporation Intestinal fibrosis treatment agent
TR201816986T4 (tr) 2012-06-08 2019-01-21 Nitto Denko Corp Terapötik ajan iletim formülasyonlarına yönelik lipitler.
EP3116512B1 (en) * 2014-03-11 2020-06-10 Dai Niann-tzyy Pharmaceutical composition and method for reducing scar formation
CN104174034A (zh) * 2014-08-20 2014-12-03 南京大学 肝星状细胞靶向的基因药物输送载体及其制备方法和应用
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
BR112018008344A2 (pt) 2015-12-13 2018-10-30 Nitto Denko Corp molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição
AU2017267634C1 (en) * 2016-05-16 2022-05-26 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
JP6833456B2 (ja) * 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
WO2018170464A1 (en) * 2017-03-17 2018-09-20 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of tgfb2 expression
WO2020181130A2 (en) * 2019-03-05 2020-09-10 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof
TWI740533B (zh) 2020-06-11 2021-09-21 國立中央大學 評估個體罹患腹膜硬化症之風險的方法、其分析器及其套組
BR112022026302A2 (pt) * 2020-06-24 2023-01-17 Bristol Myers Squibb Co Processo para síntese de moléculas-alvo
WO2022040782A1 (en) * 2020-08-25 2022-03-03 Laurent Pharmaceuticals Inc. Use of fenretinide or an analogue thereof to treat pulmonary fibrosis
JP2025504092A (ja) * 2022-02-04 2025-02-06 ニューヨーク ユニバーシティ 心房細動の処置のためのレチノイドの使用
EP4504231A1 (en) 2022-04-08 2025-02-12 University of North Texas Health Science Center at Fort Worth Treatment for ocular fibrosis
WO2024059714A1 (en) * 2022-09-15 2024-03-21 Bristol-Myers Squibb Company Method of treating advanced hepatic fibrosis associated with hcv infection with targeted lipid nanoparticle compositions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
KR970005898B1 (ko) 1987-09-21 1997-04-21 젠- 프로우브 인코퍼레이티드 뉴클레오티드 프로브에 대한 비-뉴클레오티드 연결시약
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
EP0618925B2 (en) 1991-12-24 2012-04-18 Isis Pharmaceuticals, Inc. Antisense oligonucleotides
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
ATE227342T1 (de) 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
CA2174339A1 (en) 1993-10-27 1995-05-04 Lech W. Dudycz 2'-amido and 2'-peptido modified oligonucleotides
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
AU4412096A (en) 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19640092A1 (de) 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
NZ513402A (en) 1999-02-12 2003-06-30 Sankyo Co Novel nucleosides and oligonucleotide analogues
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
DE10012151A1 (de) 2000-03-13 2001-09-27 Gsf Forschungszentrum Umwelt Mittel zur Behandlung von Erkrankungen des Tracheo-Brochialtraktes, insbesondere der COPD
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
JP2005507934A (ja) 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
AUPR894201A0 (en) 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
PT1527176E (pt) 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
JP4755972B2 (ja) 2003-03-21 2011-08-24 サンタリス ファーマ アー／エス 短鎖干渉ＲＮＡ（ｓｉＲＮＡ）アナログ
WO2004089311A2 (en) 2003-03-31 2004-10-21 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
JP5243789B2 (ja) 2004-03-15 2013-07-24 シティ・オブ・ホープ 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
SI2727583T1 (sl) * 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
EA014886B1 (ru) * 2006-03-31 2011-02-28 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5
DE202006005347U1 (de) * 2006-04-03 2007-08-02 Efbe Elektrogeräte GmbH Infrarotleuchte
US9074205B2 (en) 2006-10-18 2015-07-07 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
JP2010527914A (ja) 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
WO2009059450A1 (en) 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
KR20110051214A (ko) 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체
TWI556831B (zh) 2008-09-12 2016-11-11 日東電工股份有限公司 纖維化疾病之造影劑
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
DK2509991T3 (en) * 2009-12-09 2015-12-21 Nitto Denko Corp MODULATION OF HSP47 EXPRESSION
CA3102008A1 (en) * 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體

Also Published As

Publication number Publication date
CA2836925A1 (en) 2012-12-13
CN103781909B (zh) 2017-12-05
US20140356413A1 (en) 2014-12-04
US20130071467A1 (en) 2013-03-21
LT3075855T (lt) 2018-09-25
PT2717921T (pt) 2016-07-08
DK2717921T3 (en) 2016-07-04
JP5873168B2 (ja) 2016-03-01
US8741867B2 (en) 2014-06-03
AU2012267472A1 (en) 2014-01-23
KR20140035997A (ko) 2014-03-24
EP3075855A1 (en) 2016-10-05
CY1117683T1 (el) 2017-05-17
WO2012170957A8 (en) 2013-12-27
CN103781909A (zh) 2014-05-07
PT3075855T (pt) 2018-10-19
US20170175115A1 (en) 2017-06-22
EP2717921B1 (en) 2016-05-18
HRP20181440T1 (hr) 2018-11-02
WO2012170957A2 (en) 2012-12-13
WO2012170957A3 (en) 2013-04-11
EP3075855B1 (en) 2018-08-15
JP2014519516A (ja) 2014-08-14
EP2717921A2 (en) 2014-04-16
TW201315473A (zh) 2013-04-16
US20130071478A1 (en) 2013-03-21
SMT201800584T1 (it) 2019-01-11
US9456984B2 (en) 2016-10-04
RU2628694C2 (ru) 2017-08-21
AU2012267472B2 (en) 2017-07-27
US8664376B2 (en) 2014-03-04
DK3075855T3 (en) 2018-10-08
CY1120685T1 (el) 2020-05-29
HRP20181440T8 (hr) 2018-12-14
ES2586593T3 (es) 2016-10-17
KR102002771B1 (ko) 2019-07-23
RS57824B1 (sr) 2018-12-31
RU2013158469A (ru) 2015-07-20
ES2689696T3 (es) 2018-11-15
SI3075855T1 (sl) 2018-10-30
TWI658830B (zh) 2019-05-11
CA2836925C (en) 2021-11-16
US10195145B2 (en) 2019-02-05
PL2717921T3 (pl) 2016-10-31
HUE039379T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
HRP20181440T1 (hr) Retinoidni liposomi, namijenjeni poboljšavanju moduliranja eksprimiranja hsp47
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
PT2906696T (pt) Métodos para modular a expressão de c9orf72
LT3461895T (lt) Ube3a-ats raiškos moduliavimas
IL238266A0 (en) Compositions for modulation of c9orf72 expression
PT2730310T (pt) Aplicador
EP2679170A4 (en) APPLICATOR
AP00290S1 (en) Applicator
GB201506603D0 (en) Photobioreactor
GB201219116D0 (en) Optical modulator
GB201410312D0 (en) Photobioreactor
GB201108481D0 (en) Electro-optic modulator
EP2768941A4 (en) photobioreactor
GB2495295B (en) Applicator
GB201109849D0 (en) Modulation
GB201102918D0 (en) Fluorescence modulators
GB201117451D0 (en) An optical modulator
PL398028A1 (pl) Fotobioreaktor
GB201105757D0 (en) Loyalty scheme
GB201011150D0 (en) Antibody modulation
GB201010976D0 (en) Antibody modulation
GB201117896D0 (en) Applicator
PL394524A1 (pl) Aplikator
GB201103906D0 (en) Novel methodology
GB201110793D0 (en) Easy carry